SAN DIEGO, March 23, 2018 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that
Amit D. Munshi, the Company's
President and Chief Executive Officer, will present a corporate
update at the 17th Annual Needham Healthcare Conference on
Tuesday, March 27 at 3:00 p.m. EDT. The conference will take
place March 27-28, 2018 at the Westin
Grand Central Hotel in New York City.
A live audio webcast of the presentation will be available under
the investor relations section of Arena's website at
www.arenapharm.com.
About Arena Pharmaceuticals
Arena Pharmaceuticals is
focused on developing novel, small molecule drugs with optimized
receptor pharmacology and pharmacokinetics designed to deliver
broad clinical utility across several therapeutic areas. Arena's
proprietary pipeline includes potentially first- or best-in-class
programs. The most advanced investigational clinical programs are
ralinepag (APD811), which is anticipated to commence a Phase 3
program for pulmonary arterial hypertension (PAH), and etrasimod
(APD334), for which the Company intends to commence a Phase 3
program for ulcerative colitis (UC) and which the Company believes
has potential utility for a broad range of immune and inflammatory
conditions. Arena is also evaluating APD371 in Phase 2 for the
treatment of pain associated with Crohn's disease. In addition,
Arena has collaborations with the following pharmaceutical
companies: Everest Medicines Limited (ralinepag and etrasimod in
Greater China and select Asian
countries), Axovant Sciences GmbH (nelotanserin - Phase 2),
Boehringer Ingelheim International GmbH (undisclosed target -
preclinical), and Eisai Co., Ltd. and Eisai Inc.
(BELVIQ® - marketed product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These forward-looking statements may be
accompanied by words such as "will," "upcoming," "focused on,"
"designed to," "potentially," "may," or words of similar meaning,
or by the fact that they do not relate strictly to historical or
current facts. Such forward-looking statements include statements
about the upcoming presentation and about Arena's focus, programs
and collaborations. For such statements, Arena claims the
protection of the Private Securities Litigation Reform Act of 1995.
Actual events or results may differ materially from Arena's
expectations. Factors that could cause actual results to differ
materially from the forward-looking statements include that
clinical programs may not proceed at the time or in the manner
expected or at all, as well as those factors disclosed in Arena's
filings with the Securities and Exchange Commission, including its
Annual Report on Form 10-K for the year ended December 31, 2017. These forward-looking
statements represent Arena's judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Corporate Contact:
Kevin R.
Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content with
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-the-17th-annual-needham-healthcare-conference-on-march-27-300618991.html
SOURCE Arena Pharmaceuticals, Inc.